BR112013032125A2 - combinação de panobinostat e ruxolitinibe no tratamento de câncer do tipo neoplasia mieloproliferativa - Google Patents

combinação de panobinostat e ruxolitinibe no tratamento de câncer do tipo neoplasia mieloproliferativa

Info

Publication number
BR112013032125A2
BR112013032125A2 BR112013032125A BR112013032125A BR112013032125A2 BR 112013032125 A2 BR112013032125 A2 BR 112013032125A2 BR 112013032125 A BR112013032125 A BR 112013032125A BR 112013032125 A BR112013032125 A BR 112013032125A BR 112013032125 A2 BR112013032125 A2 BR 112013032125A2
Authority
BR
Brazil
Prior art keywords
combination
treatment
ruxolitinib
panobinostat
relates
Prior art date
Application number
BR112013032125A
Other languages
English (en)
Inventor
Brian Gadbaw
Fabienne Baffert
Thomas Radimerski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47357438&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013032125(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112013032125A2 publication Critical patent/BR112013032125A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

resumo patente de invenção: "combinação de panobinostat e ruxolitinibe no tratamento de câncer do tipo neoplasia mieloproliferativa". a presente invenção refere-se a uma combinação que compreende: (a) composto a ((r)-3-(4-(7h-pirrol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrila) da fórmula (a): ou um de seus sais farmaceuticamente aceitáveis; e (b) composto b (n-hidróxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]metil]fenil]-2e-2-propenamida) da fórmula (b): ou um de seus sais farmaceuticamente aceitáveis; para uso simultâneo, concomitante, separado ou em sequência, especialmente para uso no tratamento de doenças proliferativas. a invenção também refere-se a composições farmacêuticas que compreendem tal combinação e a um método para tratar doenças proliferativas em um mamífero, especialmente em humano, com tal combinação. a presente invenção também ainda refere-se a uma embalagem ou produto comercial compreendendo tal combinação.
BR112013032125A 2011-06-14 2012-06-13 combinação de panobinostat e ruxolitinibe no tratamento de câncer do tipo neoplasia mieloproliferativa BR112013032125A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161496750P 2011-06-14 2011-06-14
US201161568717P 2011-12-09 2011-12-09
PCT/US2012/042174 WO2012174061A1 (en) 2011-06-14 2012-06-13 Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm

Publications (1)

Publication Number Publication Date
BR112013032125A2 true BR112013032125A2 (pt) 2016-12-13

Family

ID=47357438

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013032125A BR112013032125A2 (pt) 2011-06-14 2012-06-13 combinação de panobinostat e ruxolitinibe no tratamento de câncer do tipo neoplasia mieloproliferativa

Country Status (21)

Country Link
US (2) US20140113919A1 (pt)
EP (1) EP2720696B1 (pt)
JP (1) JP6200884B2 (pt)
KR (1) KR20140056212A (pt)
CN (1) CN103608012A (pt)
AU (2) AU2012271814A1 (pt)
BR (1) BR112013032125A2 (pt)
CA (1) CA2844407A1 (pt)
CL (1) CL2013003577A1 (pt)
CO (1) CO6821954A2 (pt)
EA (1) EA027654B1 (pt)
ES (1) ES2595407T3 (pt)
GT (1) GT201300308A (pt)
HK (1) HK1193045A1 (pt)
IL (1) IL229766A (pt)
MX (1) MX344580B (pt)
NZ (1) NZ618367A (pt)
PE (1) PE20140604A1 (pt)
SG (1) SG195141A1 (pt)
WO (1) WO2012174061A1 (pt)
ZA (1) ZA201308815B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
DK3409278T3 (da) 2011-07-21 2020-11-09 Sumitomo Dainippon Pharma Oncology Inc Heterocykliske proteinkinaseinhibitorer
JP6150813B2 (ja) 2011-11-11 2017-06-21 ノバルティス アーゲー 増殖性疾患の治療方法
WO2013078264A1 (en) 2011-11-23 2013-05-30 Novartis Ag Pharmaceutical formulations
BR112015010477A2 (pt) * 2012-11-08 2017-07-11 Novartis Ag combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
JP6479818B2 (ja) * 2013-05-10 2019-03-06 シーエヌアイシー ファンデーション セントロ ナショナル デ インベスティゲイショネス カーディオバスキュレアス カルロス ザ サード 骨髄増殖性新生物の治療に適した化合物
EP3148545B1 (en) * 2014-05-28 2023-03-15 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
ES2874537T3 (es) * 2014-08-21 2021-11-05 Ratiopharm Gmbh Sal oxalato de ruxolitinib
KR102496025B1 (ko) * 2014-09-22 2023-02-03 고쿠리츠켄큐카이하츠호진 카가쿠기쥬츠신코키코 항인플루엔자 바이러스제, 및 항인플루엔자 바이러스제의 스크리닝 방법
CZ2014773A3 (cs) * 2014-11-10 2016-05-18 Zentiva, K.S. Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu
JP6851978B2 (ja) 2015-04-20 2021-03-31 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ミトコンドリアプロファイリングによるアルボシジブ応答の予測
CN111349118B (zh) 2015-05-18 2023-08-22 住友制药肿瘤公司 具有增加的生物利用度的阿伏西地前药
US10512642B2 (en) 2015-06-04 2019-12-24 Children's Hospital Medical Center Therapeutic targeting of myeloproliferative neoplasms by DUSP1 inhibition
AU2016301315C1 (en) 2015-08-03 2022-07-07 Sumitomo Pharma Oncology, Inc. Combination therapies for treatment of cancer
WO2017196261A1 (en) * 2016-05-11 2017-11-16 National University Of Singapore Jak and hdac dual-inhibitor compounds
WO2017209766A1 (en) * 2016-06-03 2017-12-07 Q3 Medical Devices Limited Stent
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
EP3773560A4 (en) * 2018-04-13 2022-01-19 Sumitomo Dainippon Pharma Oncology, Inc. PIM KINASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND CANCER-ASSOCIATED FIBROSIS
EP3856189A4 (en) * 2018-09-25 2022-06-29 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
EP3904356A4 (en) * 2018-12-24 2022-09-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. THERAPEUTIC USE OF PYRROLOPYRIMIDINE COMPOUND, AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
WO2021154976A1 (en) * 2020-01-28 2021-08-05 Secura Bio, Inc. Methods of treating brain cancer with panobinostat
CN111407894B (zh) * 2020-02-21 2022-04-29 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种治疗复发/难治t细胞淋巴瘤的新型联合靶向药物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DK2348023T5 (da) 2005-12-13 2017-05-15 Incyte Holdings Corp Heteroaryl-substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus-kinase-inhibitorer
EP2120900A2 (en) * 2007-02-15 2009-11-25 Novartis AG Combination of lbh589 with other therapeutic agents for treating cancer
RS53245B2 (sr) * 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
EP2675451B9 (en) * 2011-02-18 2017-07-26 Novartis Pharma AG mTOR/JAK INHIBITOR COMBINATION THERAPY

Also Published As

Publication number Publication date
PE20140604A1 (es) 2014-05-13
MX344580B (es) 2016-12-20
CO6821954A2 (es) 2013-12-31
NZ618367A (en) 2016-01-29
ES2595407T3 (es) 2016-12-29
IL229766A (en) 2017-10-31
MX2013014805A (es) 2014-01-24
AU2017204469A1 (en) 2017-07-20
EP2720696B1 (en) 2016-05-25
AU2012271814A1 (en) 2013-12-12
EP2720696A1 (en) 2014-04-23
CL2013003577A1 (es) 2014-08-01
US20140113919A1 (en) 2014-04-24
KR20140056212A (ko) 2014-05-09
CN103608012A (zh) 2014-02-26
ZA201308815B (en) 2014-07-30
CA2844407A1 (en) 2012-12-20
JP6200884B2 (ja) 2017-09-20
US20180085371A1 (en) 2018-03-29
SG195141A1 (en) 2013-12-30
EA027654B1 (ru) 2017-08-31
IL229766A0 (en) 2014-01-30
HK1193045A1 (zh) 2014-09-12
EA201490016A1 (ru) 2014-04-30
GT201300308A (es) 2017-09-28
JP2014517039A (ja) 2014-07-17
WO2012174061A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
BR112013032125A2 (pt) combinação de panobinostat e ruxolitinibe no tratamento de câncer do tipo neoplasia mieloproliferativa
EA201071288A1 (ru) Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
DOP2011000203A (es) Derivados de pirimidin indol para el tratamiento de cancer
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
EA201071094A1 (ru) Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
SV2010003767A (es) Compuestos pirazolicos 436
EA201290394A1 (ru) Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7
MX2011008634A (es) Derivados de aminotetralina composiciones farmaceuticas que los contienen y su uso en terapia.
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
PE20140099A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
MX2009014235A (es) 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
MX2014000130A (es) Procedimientos y composiciones para la inhibicion de resorcion osea.
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
EA201201680A1 (ru) Морфолинопиримидины и их применение в терапии
UY32203A (es) Amino pirimidinas y su uso en terapia
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
EA200870448A1 (ru) Тризамещенные 1,2,4-триазолы
BR112014006297A2 (pt) inibidores de n-[1-ciano-2-(fenil) etil]-2-azabiciclo [2.2.1] heptano-3-carboxamida de catepsina c, seus usos, e composição farmacêutica
AR085173A1 (es) Terapia de combinacion para el tratamiento de enfermedades oncologicas y fibroticas
MX2014006004A (es) Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2518 DE 09-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.